Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

Novartis AG (NVS) a Buy on High-Level Quant Score

By Portfolio Grader
Novartis AG (NYSE:NVS) is a member of the 134 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS's market value is $200.3 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for NVS puts it 15 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 109 among the 782 companies in the sector, and number 639 in the nearly 5,000 company Portfolio Grader universe.

Weak Earnings Growth Hamper China Mobile (CHL) Rating

By Portfolio Grader
Currently, China Mobile Ltd (NYSE:CHL) has a Hold using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. CHL has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold.

How the iPhone’s Success Weakens Apple Inc. Stock

By Vince Martin, InvestorPlace Contributor
Apple's reliance on the iPhone has gotten it this far. But concerns about "commoditization" and lengthening product cycles still pose a long-term risk.

Sales Growth Restrict Verizon (VZ) Rating

By Portfolio Grader
With a $209.1 billion market value, Verizon Communication Inc (NYSE:VZ) ranks in the top 10% of its industry group, Diversified Telecommunication Services, and in the top 10% of its sector group, Telecommunication Services, in market value. From the prospective of investment attractiveness, the ranking for VZ by Portfolio Grader places it 29 among the 44 companies in this industry group, which is a below-average position; in the third quartile of the sector with a ranking of 44 among the 65 companies in the sector, and number 2,502 in the nearly 5,000 company Portfolio Grader universe.

Healthy Earnings Visibility Keep Pfizer (PFE) a Buy

By Portfolio Grader
The current recommendation of Buy for Pfizer Inc (NYSE:PFE) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Sinking Industry Group Rank Make AT&T (T) a Sell

By Portfolio Grader
AT&T Inc (NYSE:T) ranks in the top decile in its industry group, Diversified Telecommunication Services, and in the top 10% of its sector group, Telecommunication Services, with a market value of $224.1 billion. From an investment attractiveness prospective, T is ranked squarely in the bottom quartile of the sector with a ranking of 55 among the 65 companies in the sector; the stock's current Portfolio Grader ranking places it 38 among the 44 companies in this industry group, a position that is well below-average and number 3,628 in the 5000 company Portfolio Grader company universe.

Solid Sales Growth Make Chevron (CVX) a Buy

By Portfolio Grader
Portfolio Grader currently ranks Chevron Corp (NYSE:CVX) a Buy. With proprietary fundamental and quantitative metrics developed by Louis Navellier, this analytical tool assesses nearly 5,000 stocks weekly. This represents no change from the previous week and is the same ranking CVX has had from Portfolio Grader for 4 months.

Poor Quant Score Limit Exxon Mobil (XOM) Rating

By Portfolio Grader
As one of the 362 companies in the GICS Energy sector Exxon Mobil Corp (NYSE:XOM) is a constituent of the 289 company Oil Gas & Consumable Fuels GICS industry group within this sector. The market value of XOM is $353.6 billion which falls in the top 10% of its industry group. Portfolio Grader's current ranking for XOM puts it 135 among the 289 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 154 among the 362 companies in the sector, and number 2,708 in the nearly 5,000 company Portfolio Grader universe.

Johnson & Johnson’s (JNJ) Healthy Quant Score Keep it a Buy

By Portfolio Grader
Johnson & Johnson Co (NYSE:JNJ) is ranked as a Buy using the methods for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking JNJ has had from Portfolio Grader for 9 months.

The Company Is Winning, but Netflix, Inc. Stock Is No Buy

By Luce Emerson, InvestorPlace Contributor
While Netflix, Inc. (NASDAQ:NFLX) executives are quick to downplay the $6 billion current fiscal year spend that will be topped by next year’s projected $8 billion original programming budget, it remains important for investors to honestly evaluate their comfort levels around those figures.

The Home Depot Inc Stock Price Is Its Only Big Problem

By Lawrence Meyers, InvestorPlace Contributor
Just about everything is going right for HD, except that HD stock is too expensive to buy right now.

8 Happy Hanukkah Images to Post on Social Media

By Karl Utermohlen, InvestorPlace Writer
What are some of your favorite happy Hanukkah images? We have compiled the eight best ones to share on Facebook during the eight-day festival.

Analysis of Industry Group Rank Make Evolent Health (EVH) a Sell

By Portfolio Grader
Portfolio Grader currently ranks Evolent Health Inc (NYSE:EVH) a Sell. The approach to investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for 4 months.

Analysis of Industry Group Rank Make Evolent Health (EVH) a Sell

By Portfolio Grader
Portfolio Grader currently ranks Evolent Health Inc (NYSE:EVH) a Sell. The approach to investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for 4 months.

Hanukkah 2017: Facts and Traditions

By Karl Utermohlen, InvestorPlace Writer
Hannukah 2017 is coming next week and it's a holiday that celebrates one of the most important times in Jewish history, dating back millennia.

Negative Industry Group Rank Keep HMS Holdings (HMSY) a Strong Sell

By Portfolio Grader
HMS Holdings Corp (NASDAQ:HMSY) ranks in the top half of its industry group, Health Care Technology, and in the top half of its sector group, Health Care, with a market value of $1.4 billion. From an investment attractiveness viewpoint, HMSY is ranked squarely in the bottom quartile of the sector with a ranking of 721 among the 782 companies in the sector; the stock's Portfolio Grader ranking currently places it 24 among the 24 companies in this industry group, a spot that is well below-average and number 4,293 in the 5000 company Portfolio Grader company universe.

7 Major Investors That Are Terrified of Bitcoin

By Will Ashworth, InvestorPlace Contributor
It seems everyone’s got an opinion about bitcoin both for and against its use. Here are seven major investors who avoid the cryptocurrency.

Negative Industry Group Rank Keep HMS Holdings (HMSY) a Strong Sell

By Portfolio Grader
HMS Holdings Corp (NASDAQ:HMSY) ranks in the top half of its industry group, Health Care Technology, and in the top half of its sector group, Health Care, with a market value of $1.4 billion. From an investment attractiveness viewpoint, HMSY is ranked squarely in the bottom quartile of the sector with a ranking of 721 among the 782 companies in the sector; the stock's Portfolio Grader ranking currently places it 24 among the 24 companies in this industry group, a spot that is well below-average and number 4,293 in the 5000 company Portfolio Grader company universe.

Omnicell (OMCL) a Buy on Superior Quant Score

By Portfolio Grader
Omnicell Inc (NASDAQ:OMCL) is a $2.0 billion in market value component of the Health Care Technology GICS industry group where Portfolio Grader's current ranking for OMCL puts it 5 among the 24 companies in this industry group, giving it a well above-average position. OMCL is ranked in the top decile of the sector with a ranking of 75 among the 782 companies in the sector and number 462 in the 5000 company Portfolio Grader company universe.
Load More Articles